EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world outcomes of TMVR-eligible and TMVR-ineligible patients

Edoardo Zancanaro iD, Nicola Buzzatti iD, Nicolò Azzola Guicciardi, Paolo Denti iD, Eustachio Agricola iD, Francesco Ancona iD, Ottavio Alfieri iD, Michele De Bonis iD, Francesco Maisano, Roberto Lorusso

European Heart Journal - Imaging Methods and Practice · 06.10.2025 · 3 (4)

DOI: 10.1093/ehjimp/qyaf098 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Heart Journal - Imaging Methods and Practice, online erschienen am 06.08.2025. Verfasst von Edoardo Zancanaro und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac Surgery, San Raffaele Scientific Institute, Via olgettina 69, Milano 20140, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Over the past decade, transcatheter valve replacement has emerged as a therapy for selected patients with valvular heart. Clinical experience with transcatheter mitral valve replacement (TMVR) has been limited to date and provides little insight into its potential as a viable therapy for MR. The present study aims to analyze the current longest follow-up real-life outcomes of TMVR procedures with a specific focus on the patient population left untreated due to the unfeasibility of the procedure.

Results

Out of 3400 patients referred for mitral pathology, 88 were screened for TMVR procedure, being unfeasible for surgical and TEER procedure (Transcatheter Edge-to-Edge Repair). 37 pts (45%) were screened positive and treated with TMVR; 30 (81%) with Tendyne system (Abbott) and 7 (19%) with Tiara. For cardiac death, in TMVR the survival was 97.2%, 90.7%, and 90.7% at 1, 2, and 4 years, respectively. Concerning MT, instead, it was 86.4%, 77%, and 42% at 1, 2, and 4 years, respectively. A difference is seen between the two groups, P-value 0.024.

Conclusion

TMVR is a valid option in selected patients and give valid longer follow-up results. The TMVR-ineligible patients showed a progressive detrimental worse survival across the follow-up.

Schlagwörter

Stichwörter der Autor:innen

MRTENDYNETMVRmitral

Autor:innen und Institutionen

  • Department of Cardiac Surgery, San Raffaele Scientific Institute, Via olgettina 69, Milano 20140, Italy.
  • Cardiovascular Imaging Unit, San Raffaele Scientific Institute, Via olgettina 69, Milano 20140, Italy.
  • Cardiovascular Research Institute (CARIM), University of Maastricht, UNS 50, Room H1, Universiteitssingel 50, 632, 6229 ER Maastricht, The Netherlands.
  • Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, The Netherlands.

ORCID-Profile: Edoardo Zancanaro, Nicola Buzzatti, Paolo Denti, Eustachio Agricola, Francesco Ancona, Ottavio Alfieri, Michele De Bonis

Zitieren

APA

Zancanaro, E., Buzzatti, N., Guicciardi, N. A., Denti, P., Agricola, E., Ancona, F., Alfieri, O., De Bonis, M., Maisano, F., & Lorusso, R. (2025). Real-world outcomes of TMVR-eligible and TMVR-ineligible patients. European Heart Journal - Imaging Methods and Practice, 3(4). https://doi.org/10.1093/ehjimp/qyaf098

Vancouver

Zancanaro E, Buzzatti N, Guicciardi NA, Denti P, Agricola E, Ancona F, et al. Real-world outcomes of TMVR-eligible and TMVR-ineligible patients. European Heart Journal - Imaging Methods and Practice. 2025;3(4). doi:10.1093/ehjimp/qyaf098

BibTeX
@article{Zancanaro2025,
  author = {Zancanaro, Edoardo and Buzzatti, Nicola and Guicciardi, Nicolò Azzola and Denti, Paolo and Agricola, Eustachio and Ancona, Francesco and Alfieri, Ottavio and De Bonis, Michele and Maisano, Francesco and Lorusso, Roberto},
  title = {Real-world outcomes of TMVR-eligible and TMVR-ineligible patients},
  journal = {European Heart Journal - Imaging Methods and Practice},
  year = {2025},
  volume = {3},
  number = {4},
  doi = {10.1093/ehjimp/qyaf098}
}
Kostenlos starten →